UK's Regenerative Medicine Sector Gets a Boost
UK regenerative medicine companies are being offered the opportunity to compete for an investment package designed to enable them to boost their productivity. The government-backed Technology Strategy Board has launched a £1.5m collaborative R&D competition call, setting businesses the challenge of developing a better understanding of the best ways to make a profit from regenerative medicine.
Zahid Latif, Lead Technologist in Biosciences, Medicines and Healthcare for the Technology Strategy Board said:
“Regenerative medicine companies operate in an emerging business sector, in an international environment where delivery of regenerative medicine could take on a number of different guises as the products and services are developed. The number of UK companies working in this field has been growing since 2003 and we are a world leader in this area, with a strong academic science base and a supportive clinical and regulatory environment.”
“There has been much recent progress but if the UK is to fulfill its potential, there are a number of development challenges which need to be overcome to successfully commercialize promising discoveries,” he added.
The competition is designed to encourage businesses to explore where and how value is created in the regenerative medicine value chain and develop business models to enable them to best capture that value, for themselves and the UK economy as a whole.
The Technology Strategy Board is a business-led executive nondepartmental public body, established by the government. Its role is to promote and support research into, and development and exploitation of, technology and innovation for the benefit of UK business to increase economic growth and improve the quality of life. It is sponsored by the Department for Business, Innovation and Skills (BIS). For more information visit www.innovateuk.org.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
